While the above mentioned studies investigated stem cell subsets defined by the normal immunophenotypic profile of the HSC, other research groups have shown aberrant marker‐expression on CD34+CD38− cells in MDS, although only in minor fractions of patients (Florian et al, 2006; Xie et al, 2010; Li et al, 2014). This evidence concerns the gene CD34 and myelodysplastic syndrome.